CN1340360A - Immunoactive yolk-albumen composition - Google Patents
Immunoactive yolk-albumen composition Download PDFInfo
- Publication number
- CN1340360A CN1340360A CN 00125941 CN00125941A CN1340360A CN 1340360 A CN1340360 A CN 1340360A CN 00125941 CN00125941 CN 00125941 CN 00125941 A CN00125941 A CN 00125941A CN 1340360 A CN1340360 A CN 1340360A
- Authority
- CN
- China
- Prior art keywords
- complex
- enterotoxin
- immunoglobulin
- lysozyme
- ovotransferrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
An immunoactive yolk-albumen composition for supplementing nutrients to human body, suppressing the pathogenic bacteria in intestinal tract and improving disease resistance contains antienterotoxin immunoglobulin (45-55 wt.%), ovum converted Fe protein (17-23), lysozyme (17-23), and the rest being water, ash and trace elements. The said antienterotoxin immunoglobulin has molecular weigh of 172 KD and is composed of two heavy chains and two light chains.
Description
The present invention relates to protein complex.
Egg nutrient is worth high, and edible back is to replenishing the human nutrition element, and health invigorating is beneficial.But people do not extract a kind of material with higher effect as yet from egg so far, and this material element that can supplement the nutrients can suppress, engulf the pathogenic bacteria in the intestinal again.Also unprecedented this complex of the present invention in the known technology.
The object of the present invention is to provide a kind of contain several amino acids and trace element, can suppress after edible, the crystal type albumen composition of the interior pathogenic bacteria of phagosome.
Its special character of technical solution of the present invention is to contain following component: anti-enterotoxin immunoglobulin, ovotransferrin and lysozyme.
Complex of the present invention contains moisture, ash and the trace element of anti-enterotoxin immunoglobulin 45～55%, ovotransferrin 17～23%, lysozyme 17～23% and surplus in its gross weight.
Described complex is in its gross weight, and preferred ingredients content is moisture, ash and the trace element of anti-enterotoxin immunoglobulin 50%, ovotransferrin 20%, lysozyme 20% and surplus.
Complex of the present invention, described its molecular structure pattern of anti-enterotoxin immunoglobulin is:
Its molecular weight is 172KD (1720000), is 2 heavy chain H and 2 light chain L, becomes the Y font, light chain L molecular weight～23KD (230000) wherein, heavy chain H molecular weight～63KD (630000).
Complex of the present invention is produced through the method: adopt the cell bacterium of enterotoxin class to make antigen, be prepared into vaccine, the ratio of Escherichia coli and Salmonella is 60: 40, bird inlay is regularly strengthened injection, after the nursing of a period of time, hen lays eggs that the egg yolk of getting dilutes, flocculation, centrifugal filtration, ultrafiltration, microfiltration, lyophilization form.
Described complex is a crystalline solid, is baby pink, free from extraneous odour.Wherein:
The effect of anti-enterotoxin immunoglobulin: can coagulation, engulf and in and antibacterial and eliminating toxin composition, can kill or suppress common pathogenic entero becteria, as staphylococcus aureus, bacillus pyocyaneus, streptococcus, Salmonella;
The effect of ovotransferrin: can promote lymphocytic growth, prevent or suppress the pathogenic bacterium intrusion, can regulate and promote the bifidobacterium breve growth, can in conjunction with and carry iron ion, thereby the promotion infant effectively prevents anemia to the absorption of ferrum; Can suppress the generation of interior free yl, have the antidotal effect of alleviating rheumatoid arthritis;
The effect of lysozyme: preventing enteritis and allergy effect, is the bacillus bifidus growth factor, and the intestinal microbial population of infant is had balanced action; Has the effect of decomposing gram positive bacteria; Effect with caries prevention is the very high food antibacterial of a kind of safety.
Complex of the present invention, its total protein content can be up to 90%, and various amino acid contents are by (100 gram these complex amino acid contained gram number) shown in the table 1:
Table 1
| The aminoacid title | Content (g/100g) |
| It six winters propylhomoserin | ?????9.48 |
| Threonine | ?????4.36 |
| Serine | ?????5.80 |
| Glutamic acid | ?????12.21 |
| Glycine | ?????3.05 |
| Alanine | ?????5.26 |
| Cystine | ?????3.59 |
| Valine | ?????6.00 |
| Methionine | ?????3.26 |
| Isoleucine | ?????3.77 |
| Leucine | ?????7.04 |
| Tyrosine | ?????3.52 |
| Phenylalanine | ?????3.81 |
| Lysine | ?????6.88 |
| Histidine | ?????2.47 |
| Arginine | ?????4.42 |
| Tryptophan | ?????0.89 |
| Proline | ?????4.17 |
| Total amino acids | ?????89.98 |
The contained trace element of complex of the present invention is by (every kilogram complex contained milligram number) shown in the table 2:
Table 2
| Composition | Content (mg/kg) |
| ????Co | ?????0.062 |
| ????Cd | ?????0.032 |
| ????Mg | ?????145 |
| ????Cu | ?????3.47 |
| ????Zn | ?????10.6 |
| ????Fe | ?????42.7 |
| ????Pb | ?????0.036 |
| ????Cr | ?????2.38 |
Complex of the present invention owing to be rich in anti-enterotoxin immunoglobulin, so have the antibody of anti-enterotoxin, again owing to contain ovotransferrin and lysozyme, and have tangible gathering antibacterial with the effect of engulfing antibacterial.The main effect and the effect of this bright complex: can suppress the pathogenic bacterial strains in the human body intestinal canal, and it is had phagocytosis; Effect with treatment diarrhoea and enteritis improves the disease resistance ability of human body effectively; Complex of the present invention has no side effect, no hormone, and human body does not have any dependency to this product, is the activated protein that human body obtains the protectiveness passive immunity.
This product usage: the baby directly reconstitutes oral, and child, adult take after the meal or behind the full abdomen, exempt to reconstitute with hot water more than 50 ℃, avoid mixing with strong acid, highly basic.
Claims (5)
1, immunoactive yolk-albumen composition is characterized in that containing following component: anti-enterotoxin immunoglobulin, ovotransferrin and lysozyme.
2, complex as claimed in claim 1 is characterized in that containing in this complex gross weight moisture, ash and the trace element of anti-enterotoxin immunoglobulin 45～55%, ovotransferrin 17～23%, lysozyme 17～23% and surplus.
3, complex as claimed in claim 1 is characterized in that containing in this complex gross weight moisture, ash and the trace element of anti-enterotoxin immunoglobulin 50%, ovotransferrin 20%, lysozyme 20% and surplus.
4, as claim 1,2 or 3 described complex, it is characterized in that described anti-its molecular weight of enterotoxin immunoglobulin is 172KD (1720000), is 2 heavy chain H and 2 light chain L, becomes the Y font, light chain L molecular weight～23KD (230000) wherein, heavy chain H molecular weight～63KD (630000).
5, complex as claimed in claim 4, it is characterized in that this complex produces through the method: adopt the cell bacterium of enterotoxin class to make antigen, be prepared into vaccine, the ratio of Escherichia coli and Salmonella is 60: 40, bird inlay is regularly strengthened injection, after the nursing of a period of time, hen lays eggs that the egg yolk of getting dilutes, flocculation, centrifugal filtration, ultrafiltration, microfiltration, lyophilization form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00125941 CN1340360A (en) | 2000-08-31 | 2000-08-31 | Immunoactive yolk-albumen composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00125941 CN1340360A (en) | 2000-08-31 | 2000-08-31 | Immunoactive yolk-albumen composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1340360A true CN1340360A (en) | 2002-03-20 |
Family
ID=4591705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00125941 Pending CN1340360A (en) | 2000-08-31 | 2000-08-31 | Immunoactive yolk-albumen composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1340360A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101605453B (en) * | 2007-02-15 | 2011-10-26 | 国立大学法人冈山大学 | Pest control using lysozyme, salt or biological fragment thereof or lysozyme-related peptide as egg recognition pheromone |
| CN111803628A (en) * | 2020-07-24 | 2020-10-23 | 尤丽康（江苏）生物医药有限公司 | Helicobacter pylori resisting compound preparation |
-
2000
- 2000-08-31 CN CN 00125941 patent/CN1340360A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101605453B (en) * | 2007-02-15 | 2011-10-26 | 国立大学法人冈山大学 | Pest control using lysozyme, salt or biological fragment thereof or lysozyme-related peptide as egg recognition pheromone |
| CN111803628A (en) * | 2020-07-24 | 2020-10-23 | 尤丽康（江苏）生物医药有限公司 | Helicobacter pylori resisting compound preparation |
| CN111803628B (en) * | 2020-07-24 | 2021-05-14 | 尤丽康（江苏）生物医药有限公司 | Helicobacter pylori resisting compound preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106721843B (en) | Double-bacterial protein solid beverage | |
| TWI622352B (en) | Composition comprising heat labile milk proteins and process for preparing same | |
| CN102781460A (en) | Agent for preventing muscular atrophy | |
| AU657763B2 (en) | Trace element-rich additive, method for preparing same, preparation in which the additive is included and use thereof | |
| CN110637942A (en) | Laying hen premix rich in amino acid eggs and production method and application thereof | |
| CN104824426A (en) | Preparation method of sheep feed additive fermented by probiotic | |
| CN103815018A (en) | Yak yoghourt and preparation method thereof | |
| CN105876141A (en) | Feed added with protein-mulberry leaf additive for reducing cholesterol contents of livestock meat, poultry meat and eggs as well as preparation method thereof | |
| JPH01221319A (en) | Composition for promoting enteral colonization -of useful bacteria and method therefor | |
| CN112136992A (en) | Milk-derived polypeptide compound protein beverage formula for reducing pressure and promoting sleep | |
| CN1340360A (en) | Immunoactive yolk-albumen composition | |
| KR20080054912A (en) | The process of manufacturing fermented soybeans pill | |
| JPH06247871A (en) | Growth promoter | |
| Önür et al. | 4. INNOVATIVE PRODUCTS PRODUCED FROM WHEY | |
| CN101564174A (en) | Protein powder corrected by humanized amino acid spectrum | |
| CN113558148B (en) | Snow swallow product for cats as well as preparation method and application thereof | |
| JPH11127815A (en) | Health maintenance by combination of certain oligosaccharide and tea fermented with microorganism | |
| KR20200058174A (en) | Manufacture method of spirulina extracts | |
| KR102534536B1 (en) | Composition and manufacturing method effective for antibacterial, antioxidant, and immunity enhancement using Probiotics Lactobacillus and red ginseng in the intestine of companion animal | |
| JP3789146B2 (en) | Oligosaccharide-containing nutritional composition | |
| CN112961895B (en) | Black food fermentation type composite small molecular peptide, oral liquid, preparation method and application | |
| JPH04365444A (en) | Antiallergic formulated milk | |
| WO2005112657A1 (en) | Method of making protein hydrolysates enriched in aminoacids and the use thereof for the production of functional food and medical food | |
| CN105146369A (en) | Nutrition bag capable of adjusting intestine micro-ecological environment and relieving slow growth caused by lack of nutrients of babies | |
| CN114145393A (en) | Intestinal microecological preparation and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |